LA JOLLA, CA, April 30, 2024 – Enlaza Therapeutics, the first covalent biologic platform company, today announced a $100 million Series A financing. The financing will be used to further...
Athersys is a clinical-stage biotechnology company that has established a pipeline of therapeutic product development programs in multiple disease indications. The company’s product portfolio consists of MultiStem, a non-embryonic stem cell-based approach for treating disease indications in the areas of inflammatory and immune, neurological and cardiovascular disease.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.